AstraZeneca Arimidex supplemental NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca submits Arimidex sNDA March 4 for adjuvant treatment of early breast cancer in postmenopausal women. The company is requesting priority review for the application, which is based on results from the 9,300-woman ATAC study (Pharmaceutical Approvals Monthly, February 2002, p. 19